Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about LENZ, unsubscribe in one click. Privacy
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Aceclidine FDA approved Jul 2025 · Vizz |
Presbyopia | Phase 3 · NCT05728944 | Completed |
| Aceclidine ophthalmic solution | Presbyopia | Phase 3 · NCT05728944 | Completed |
| Brimonidine | Presbyopia | Phase 3 · NCT05656027 | Completed |
| PRX-100 | Presbyopia | Phase 2 · NCT02554396 | Completed |
| LNZ100 (Aceclidine) ophthalmic solution | Presbyopia | Phase 1 · NCT06270030 | Completed |
| LNZ101 (Aceclidine /Brimonidine) ophthalmic… | Presbyopia | Phase 1 · NCT06270030 | Completed |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
LENZ holds $197.3M in cash and short-term investments (as of Sep 30, 2026) and burns about $30.5M/quarter from operations, an estimated runway of 19.4 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 33 · Moderate
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when LENZ files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| BML Investment Partners, L.P. | 5%+ holder (13G) | 2,110,727 | 6.72% | 2026-11-02 |
| Versant Venture Capital VI, L.P. 10% owner |
Insider | 1,892,761 | 6.02% | 2025-09-30 |
| BlackRock, Inc. | Institution (13G, 5%+) | 1,804,099 | 5.74% | 2026-03-31 |
| BlackRock Portfolio Management LLC | Institution (13G, 5%+) | 1,645,489 | 5.24% | 2026-09-30 |
| Squarepoint Ops LLC | Institution (13G, 5%+) | 1,593,246 | 5.07% | 2026-04-01 |
| James W Mccollum Director · +35,600 options |
Insider | 631,099 | 2.01% | 2025-11-07 |
| Evert B. Schimmelpennink President, CEO and Secretary, Director · +975,106 options |
Insider | 77,289 | 0.25% | 2026-03-27 |
| RA CAPITAL MANAGEMENT, L.P. 10% owner · +35,600 options |
Insider | 57,559 | 0.18% | 2026-10-29 |
| Daniel R. Chevallard Chief Financial Officer · +820,707 options |
Insider | 12,886 | 0.04% | 2026-03-27 |
| Jeffrey P. George Director · +35,600 options |
Insider | 5,592 | 0.02% | 2026-03-27 |
| Shawn Olsson Chief Commercial Officer · +231,541 options |
Insider | 4,733 | 0.02% | 2025-11-17 |
Share count 31,420,583 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Date | Drug | Type | Run-up 30d | Decision 1d | After 5d |
|---|---|---|---|---|---|
| 2025-09-30 | VIZZ | NDA | +17.5% | +3.8% | +2.7% |
| 2025-08-08 | — | NDA | -7.8% | +8% | +27.4% |
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for LENZ and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →